China Pharma Holdings Inc(CPHI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.42 | Insider Own | 6.23% | Shs Outstand | 40.5M | Perf Week | -9.7% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 40.3M | Perf Month | -32.48% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | - | Inst Own | 0.47% | Short Float | 1.55% | Perf Quarter | -1.27% |
| Income | -0.00B | P/S | 8.39 | EPS this Y | - | Inst Trans | 479.65% | Short Ratio | 0.14 | Perf Half Y | 23.82% |
| Sales | 0.00B | P/B | 0.85 | EPS next 5Y | - | ROA | -15.21% | Short Interest | 0.62M | Perf YTD | -36.94% |
| Book/sh | 0.9 | P/C | 105.88 | EPS past 3/5Y | 73.01% 53.14% | ROE | -20.81% | 52W High | -96.02% ($19.19) | Perf Year | -58.31% |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | -20.03% -17.53% | ROIC | -12.28% | 52W Low | 99.84% ($0.38) | Perf 3Y | -89.19% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 71.83% | Gross Margin | -47.35% | Volatility(W/M) | 4.7% 7.13% | Perf 5Y | -99.77% |
| Dividend TTM | - | EV/Sales | 9.32 | Sales Y/Y TTM | -10.97% | Oper. Margin | -111.84% | ATR (14) | 0.21 | Perf 10Y | -99.35% |
| Dividend Ex-Date | - | Quick Ratio | 0.08 | EPS Q/Q | 77.78% | Profit Margin | -114.33% | RSI (14) | 42.58 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.26 | Sales Q/Q | -7.55% | SMA20 | -18.27% ($0.93) | Beta | 1.03 | Target Price | - |
| Payout | - | Debt/Eq | 0.11 | Earnings | - | SMA50 | -33.68% ($1.15) | Rel Volume | 0.02 | Prev Close | $0.78 |
| Employees | 221 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -21.34% ($0.97) | Avg Volume(3M) | 4.46M | Price | $0.76 |
| IPO | 2002/4/17 | Option/Short | No/Yes | Trades | 227 | Volume | 102,198 | Change | -2.05% |
Company
CPHI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 China Pharma Holdings is a U.S.-listed, China-based small-cap pharmaceutical company that manufactures and sells generic and specialty drugs through its subsidiary **Hainan Helpson**, located in Haikou, Hainan Province, China. It produces injectables, tablets, capsules, and cephalosporin oral formulations targeting cardiovascular, central nervous system, infectious, and gastrointestinal disease areas, and is also working on the commercialization of a medical device for treating dry eye syndrome. It is a micro-cap stock listed on the NYSE American.
Over the past 1 year, on the lower side
96% below its 1-year high.
CPHI has weak earning power
-111.84% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Would have changed by -89.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.5%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $33M.
CPHI $33M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is CPHI?
CPHI belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CPHI?
The market cap of CPHI is approximately $33M, ranking 5,117 within its sector.
What is the 52-week high and low for CPHI?
CPHI has recorded a 52-week high of $19.19 and a low of $0.38.
